<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Cilostazol is clinically used for the treatment of ischemic symptoms in patients with <z:hpo ids='HP_0011010'>chronic</z:hpo> peripheral arterial obstruction and for the secondary prevention of <z:e sem="disease" ids="C0751955" disease_type="Disease or Syndrome" abbrv="">brain infarction</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>Recently, it has been reported that cilostazol has preventive effects on atherogenesis and decreased serum <z:chebi fb="0" ids="17855">triglyceride</z:chebi> in <z:e sem="disease" ids="C1519106" disease_type="Experimental Model of Disease" abbrv="">rodent models</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>There are, however, few reports on the evaluation of cilostazol using atherosclerotic rabbits, which have similar <z:chebi fb="23" ids="18059">lipid</z:chebi> metabolism to humans, and are used for investigating the <z:chebi fb="23" ids="18059">lipid</z:chebi> content in aorta and platelet aggregation under conditions of <z:hpo ids='HP_0003077'>hyperlipidemia</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>Therefore, we evaluated the effect of cilostazol on the <z:hpo ids='HP_0002621'>atherosclerosis</z:hpo> and platelet aggregation in rabbits fed a <z:mpath ids='MPATH_458'>normal</z:mpath> diet or a cholesterol-containing diet supplemented with or without cilostazol </plain></SENT>
<SENT sid="4" pm="."><plain>We evaluated the effects of cilostazol on the atherogenesis by measuring serum and aortic <z:chebi fb="23" ids="18059">lipid</z:chebi> content, and the lesion area after a 10-week treatment and the effect on platelet aggregation after 1- and 10-week treatment </plain></SENT>
<SENT sid="5" pm="."><plain>From the <z:chebi fb="23" ids="18059">lipid</z:chebi> analyses, cilostazol significantly reduced the total cholesterol, <z:chebi fb="0" ids="17855">triglyceride</z:chebi> and <z:chebi fb="1" ids="16247">phospholipids</z:chebi> in serum, and moreover, the <z:chebi fb="0" ids="17855">triglyceride</z:chebi> content in the atherosclerotic aorta </plain></SENT>
<SENT sid="6" pm="."><plain>Cilostazol significantly reduced the intimal atherosclerotic area </plain></SENT>
<SENT sid="7" pm="."><plain>Platelet aggregation was enhanced in cholesterol-fed rabbits </plain></SENT>
<SENT sid="8" pm="."><plain>Cilostazol significantly inhibited the platelet aggregation in rabbits fed both a <z:mpath ids='MPATH_458'>normal</z:mpath> diet and a high cholesterol diet </plain></SENT>
<SENT sid="9" pm="."><plain>Cilostazol showed anti-atherosclerotic and anti-platelet effects in cholesterol-fed rabbits possibly due to the improvement of <z:chebi fb="23" ids="18059">lipid</z:chebi> metabolism and the attenuation of platelet activation </plain></SENT>
<SENT sid="10" pm="."><plain>The results suggest that cilostazol is useful for prevention and treatment of atherothrombotic diseases with the <z:chebi fb="23" ids="18059">lipid</z:chebi> abnormalities </plain></SENT>
</text></document>